Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes
Phase of Trial: Phase IV
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms HARUKAS
- 16 Apr 2018 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 17 Oct 2016 Status changed from recruiting to active, no longer recruiting.